|
** Waist to height ratio is a better predictor of proteinuria among Aborigines than other anthropometric measurements
Mrs Jennifer L Nicol, Centre for Chronic Disease, University of Queensland, Australia
|
|
** Cancer among Australians receiving dialysis treatment – outcome of data matching between ANZDATA and the National Cancer Statistics Clearing House (NCSCH)
A/Prof Stephen P McDonald, ANZDATA Registry, Adelaide, Australia
|
|
** Reductions in the risks of vascular events and stroke in patients with and without Chronic Kidney Disease; New data from the PROGRESS trial
Vlado Perkovic, The George Institute, Australia
|
|
** Determinants of proteinuria after conversion from a calcineurin inhibitor- to sirolimus-based immunosuppressive regimen: results from the CONVERT trial
Dr Bruce Pussell, Prince of Wales Hospital, Randwick, Australia
|
|
** The burden of chronic kidney disease in Australian patients with type 2 diabetes (NEFRON-1)
A/Prof Merlin C Thomas, Baker Heart Research Institute, Australia
|
|
** Atrial Fibrillation in Haemodialysis Patients: Do the Guidelines for Anticoagulation Apply?
Maha Yehia, Auckland City Hospital, New Zealand
|
|
Successful Combined Renal-Pancreas-Adrenal Transplantation for polyglandular autoimmune syndrome with Type I Diabetes and Nephropathy and Primary Addison’s disease
Dr Jaquelyne T Hughes, Department of Renal Medicine, The Prince of Wales Hospital, Australia
|
|
Renal Outcomes in Lung and Heart/Lung Transplant Recipients
Dr Katherine A Barraclough, Alfred Hospital, Australia
Dr Solomon Menahem, Alfred Hospital, Melbourne, Australia
|
|
The value of serum neopterin and interleukin-12B 1188A/C genotyping in predicting acute renal allograft rejection
George K Chin, Derriford Hospital, Plymouth, United Kingdom
|
|
Diagnostics and outcomes of chronic humoral rejection
Dr Patrick J Cooney, Monash Medical Centre, Australia
|
|
Desensitization of donor specific antibodies, monitoring by Luminex and ELISA and subsequent successful living kidney transplantation: two case reports
Dr Jordan Li, The Queen Elizabeth Hospital, Australia
|
|
Cancer among Australian kidney transplant recipients – outcome of data matching between ANZDATA and the National Cancer Statistics Clearing House (NCSCH)
A/Prof Stephen P McDonald, ANZDATA Registry, Australia
|
|
Conversion to Sirolimus therapy after early cyclosporin withdrawal reduces the risk of malignancy at 5 years post renal transplantation
Dr Josette Eris, Royal Prince Alfred Hospital, Sydney, Australia
|
|
Reduced Incidence of Malignancy In Renal Transplant Recipients Converted From Calcineurin Inhibitors (CNIs) to Sirolimus (SRL) Compared With Those Who Continued CNI Therapy
Dr Bruce Pussell, Prince of Wales Hospital, Randwick, Australia
|
|
Fish oil confers little benefit on kidney transplant recipients receiving calcineurin inhibitors: A systematic review
Dr Andy KH Lim, Austin Health, Australia
|
|
Parathyroidectomy (PTx) for persistent hyperparathyroidism (HPPT) following kidney transplantation (KTx) – effects on kidney allograft function
Dr Michael G Collins, Auckland City Hospital, New Zealand
|
|
Hypophosphataemia associated with switch to mTOR inhibitor. Review of Monash Medical Centre experience in 20 renal transplant recipients
Dr Susan L Blair, Monash Medical Centre, Australia
|
|
Outcomes of Kidney Transplant Recipients on Warfarin at Time of Transplant
Jennifer S Wong, Princess Alexandra Hospital, Australia
|
|
The effect of renal transplantation on adiponectin, its isoforms and receptors
Yvonne Y Shen, Prince of Wales Hospital, Australia
|
|
Anaemia Post Renal Transplantation - Clinical Risk Factors
Dr Adam J Hedley, Department of Nephrology, Austin Health, Victoria, Australia
|